These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26936687)

  • 1. Therapeutic outcome of 6198 interferon-naïve Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs' era.
    Zayed N; Gamal Eldeen H; Elmakhzangy H; Seif M; El-Akel W; Awad T; Esmat G; Mabrouk M
    J Viral Hepat; 2016 Jul; 23(7):506-11. PubMed ID: 26936687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens.
    El Kassas M; Alboraie M; Omran D; Salaheldin M; Wifi MN; ElBadry M; El Tahan A; Ezzat S; Moaz E; Farid AM; Omar H; Abouelkhair M; Afify S; Elsaeed K; Shazly Y; Doss W; Esmat G
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1265-1272. PubMed ID: 29757684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
    J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C.
    Zayed N; Awad AB; El-Akel W; Doss W; Awad T; Radwan A; Mabrouk M
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):254-61. PubMed ID: 23141214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
    Núnez M; Camino N; Ramos B; Berdún MA; Barreiro P; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Martín-Carbonero L; Romero M; García-Samaniego J; Soriano V
    Antivir Ther; 2005; 10(5):657-62. PubMed ID: 16152759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients.
    Abd El-Wahab EW; Mikheal A; Sidkey F; Shatat HZ
    J Med Virol; 2015 Mar; 87(3):428-40. PubMed ID: 25583244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
    Naga M; Amin M; Algendy D; Elbadry A; Fawzi M; Foda A; Esmat S; Sabry D; Rashed L; Gabal S; Kamal M
    World J Gastroenterol; 2015 Oct; 21(39):11141-51. PubMed ID: 26494968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4.
    Zekri AR; El-Din HM; Bahnassy AA; Khaled MM; Omar A; Fouad I; El-Hefnewi M; Thakeb F; El-Awady M
    Virol J; 2007 Feb; 4():16. PubMed ID: 17300723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
    BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.
    Picchio G; De Meyer S; Dierynck I; Ghys A; Gritz L; Kieffer TL; Bartels DJ; Witek J; Bengtsson L; Luo D; Kauffman RS; Adda N; Sarrazin C
    J Clin Virol; 2014 Mar; 59(3):148-55. PubMed ID: 24462470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
    Lagging M; Brown A; Mantry PS; Ramji A; Weilert F; Vierling JM; Howe A; Gendrano IN; Hwang P; Zhang B; Wahl J; Robertson M; Mobashery N
    J Viral Hepat; 2016 Feb; 23(2):80-8. PubMed ID: 26353843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
    Ali FT; Ali MA; Elgizawy MM; Elsawy AM
    Gut Liver; 2015 Jul; 9(4):516-24. PubMed ID: 25717047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
    Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
    Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.